News

Cell therapy for patients with amyotrophic lateral sclerosis shows promise in human trials
Dr. Simrit Parmar, an associate professor in the College of Medicine at Texas A&M University and founder of the ...
Bicara falls after early-stage trial data for head and neck cancer therapy
Bicara Therapeutics (BCAX) stock plunges as the company reports data from a Phase 1/1b trial for its lead drug ficerafusp ...
Precision Medicine Online11h
AI-Assisted IHC Scoring Improves Pathologist Agreement for HER2-Low, Ultralow Breast Cancers
In an AstraZeneca-developed training program, AI-assisted HER2 IHC scores had higher agreement with centrally confirmed scores.
Targeted Oncology11h
National Cancer Research Month: A Look at Progress and Future Directions
Manmeet Ahluwalia, MD, MBA, FASCO, discussed the significance of National Cancer Research Month and highlighted how ongoing ...
GSK wins EU backing for multiple myeloma drug, Blenrep
GSK (GSK) stock in focus as its antibody drug conjugate Blenrep gains EMA recommendation for relapsed multiple myeloma with ...
Six Abstracts of Kelun-Biotech's Clinical Studies Published at the 2025 ASCO Annual Meeting
Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, the "Company") will present results from six ...
Taiwan News20h
New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today two-year follow-up data from the phase III STARGLO study. After a median follow-up of 24.7 months, data showed a 40% improvement in overall survival ...